Novan Inc
F:6LUA
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Fu Shou Yuan International Group Ltd
HKEX:1448
|
CN |
|
Build-A-Bear Workshop Inc
NYSE:BBW
|
US |
|
P
|
Puma SE
OTC:PUMSY
|
DE |
|
Ratti SpA
MIL:RAT
|
IT |
|
Qualigen Therapeutics Inc
NASDAQ:QLGN
|
US |
Novan Inc
Capital Expenditures
Novan Inc
Capital Expenditures Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Capital Expenditures | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Novan Inc
F:6LUA
|
Capital Expenditures
-$4.3m
|
CAGR 3-Years
-117%
|
CAGR 5-Years
-15%
|
CAGR 10-Years
N/A
|
|
|
Johnson & Johnson
NYSE:JNJ
|
Capital Expenditures
-$4.8B
|
CAGR 3-Years
-6%
|
CAGR 5-Years
-8%
|
CAGR 10-Years
-3%
|
|
|
Bristol-Myers Squibb Co
NYSE:BMY
|
Capital Expenditures
-$1.3B
|
CAGR 3-Years
-5%
|
CAGR 5-Years
-12%
|
CAGR 10-Years
-5%
|
|
|
Pfizer Inc
NYSE:PFE
|
Capital Expenditures
-$2.6B
|
CAGR 3-Years
7%
|
CAGR 5-Years
1%
|
CAGR 10-Years
-6%
|
|
|
Merck & Co Inc
NYSE:MRK
|
Capital Expenditures
-$4.1B
|
CAGR 3-Years
2%
|
CAGR 5-Years
1%
|
CAGR 10-Years
-12%
|
|
|
Eli Lilly and Co
NYSE:LLY
|
Capital Expenditures
-$10.8B
|
CAGR 3-Years
-54%
|
CAGR 5-Years
-40%
|
CAGR 10-Years
-21%
|
|
Novan Inc
Glance View
Novan, Inc. is a biotechnology company, which engages in leveraging nitric oxide’s natural antiviral and immunomodulatory mechanisms of action to treat dermatological and oncovirus-mediated diseases. The company is headquartered in Durham, North Carolina and currently employs 29 full-time employees. The company went IPO on 2016-09-21. The firm is engaged in researching, developing and marketing products for skin diseases. The firm is focused on dermatology and anti-infective therapies. Its technology platform leverages nitric oxide’s naturally occurring anti-viral, anti-bacterial, anti-fungal, and immunomodulatory mechanisms of action to treat a range of diseases. The firm has clinical-stage dermatology and anti-infective drug candidates with multi-factorial (SB204), anti-viral (SB206), anti-fungal (SB208), and anti-inflammatory (SB414) mechanisms of action. The Company’s lead product candidate is SB206, which is a topical gel with anti-viral properties for the treatment of viral skin infections, with focus on molluscum contagiosum. The firm is exploring the potential of its NITRICIL technology as a potential treatment option for COVID-19, targeting the reduction of viral shedding and transmission.
See Also
What is Novan Inc's Capital Expenditures?
Capital Expenditures
-4.3m
USD
Based on the financial report for Dec 31, 2022, Novan Inc's Capital Expenditures amounts to -4.3m USD.
What is Novan Inc's Capital Expenditures growth rate?
Capital Expenditures CAGR 5Y
-15%
Over the last year, the Capital Expenditures growth was 53%. The average annual Capital Expenditures growth rates for Novan Inc have been -117% over the past three years , -15% over the past five years .
